Skye Bioscience, Inc. (SKYE) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Sky Bioscience (SKYE) Q4 2025: 22% Combo Weight Loss Drives Add-On Obesity Strategy
March 11, 2026
-
Sky Bioscience (SKYE) Q3 2025: Combo Data Delivers 30% Greater Weight Loss, Shifting Obesity Pipeline Economics
November 11, 2025
-
Sky Bioscience (SKYE) Q2 2025: $9.1M Manufacturing Spend Signals Acceleration Toward Phase 2b Obesity Data
August 08, 2025